Pfizer
PFE · What the business does, what can go wrong, and how options sellers approach it
What it does
Pfizer is a global biopharmaceutical company. It researches, develops, manufactures and sells prescription medicines and vaccines. Its products span several areas, including vaccines, heart and metabolic care, cancer treatments, and inflammation and immunology. It sells in the United States and in markets around the world, mostly through healthcare systems, wholesalers and government programs.
How it makes money
Pfizer earns revenue by selling patented drugs and vaccines, along with older medicines that have lost exclusivity. Some products are sold directly, and others are marketed with partners who share profits. Patents give a drug a period of protected pricing. After they expire, generic competition usually cuts sales sharply, so the company must keep replacing aging products with new ones. It does this through in-house research and by acquiring or licensing drugs from other companies.
Why investors own it
- Income: Pfizer has long been a dividend payer, and many investors hold it for that cash flow.
- Diversification: It sells many products across many therapeutic areas and regions, so no single drug is the whole story.
- Pipeline optionality: Successful new drugs can change the growth outlook.
- Defensive traits: Demand for medicine tends to be less tied to the economic cycle than demand for many other goods.
What can go wrong
- Patent expirations: Lost exclusivity can quickly erode revenue from major products.
- Pipeline setbacks: Clinical trials can fail, and regulators can delay or reject approvals.
- Pricing pressure: Governments and insurers push to lower drug prices.
- Demand swings: Vaccine and treatment demand can fall sharply once a health emergency fades.
- Legal and safety risks: Litigation, recalls and safety findings can hurt results.
- Acquisition risk: Deals may not deliver the value expected.
What to watch
- Progress of late-stage clinical trials
- Regulatory approvals and decisions
- Patent expiration timelines for key products
- Sales trends in core drug and vaccine franchises
- Company guidance for revenue and earnings
- Dividend coverage by earnings and cash flow
- Drug pricing policy changes
- Business development activity
Options income angle
Options on PFE are typically liquid, with many strikes and expirations and tight bid-ask spreads. Implied volatility tends to rise ahead of earnings, major clinical trial results, regulatory decisions and policy news on drug pricing. Because it is widely seen as a dividend stock, covered calls are a common strategy, though that is a general observation, not a recommendation. One caution: a single trial result or regulatory ruling can move the stock sharply, so sold calls can cap upside in a rally, and sold puts can lose money in a sudden drop.
What the latest 10-K says
A plain-English read of the Risk Factors and Management's Discussion in the 10-K for the year ended December 31, 2025, filed February 26, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The filing in brief
Pfizer's 2025 revenue slipped as COVID-19 product sales fell, while most of the rest of the portfolio grew. The filing stresses that a significant reduction in revenue from patent and regulatory exclusivity expiries is expected from 2026 through 2030, along with new U.S. drug pricing pressure. Management is leaning on cost cuts, acquisitions in obesity and oncology, and the pipeline to offset that.
How the business did
- Total revenues were $62.6 billion, a decrease of 2% from $63.6 billion in 2024. Excluding Comirnaty and Paxlovid, Total revenues increased 6% operationally (meaning excluding currency effects).
- Paxlovid was $2,362 million, down 59% operationally, and Comirnaty was $4,367 million, down 20%. Growth came from the Vyndaqel family ($6,380 million, up 16%), Eliquis ($7,961 million, up 7%), Padcev, Lorbrena and Abrysvo.
- Reported diluted EPS was $1.36, a decrease of 3%. Adjusted diluted EPS, a non-GAAP measure that strips out items like amortization and one-time charges, was $3.22, an increase of 4%. Pre-tax income fell to $7.5 billion from $8.0 billion, mainly on higher intangible asset impairment charges, a $1.35 billion in-licensing charge tied to 3SBio, and losses on equity securities.
- Net cash from operations was $11.7 billion, down 8%. Pfizer made no share repurchases in 2025, with $3.3 billion of authorization remaining, and declared a first-quarter dividend of $0.43 per share. It paid $6.9 billion for Metsera, net of cash acquired, and sold its remaining Haleon stake for $6.3 billion.
Risks specific to this company
- Product concentration: 12 products each had revenues of more than $1 billion and together made up 65% of Total revenues. Eliquis alone was 13%.
- Loss of exclusivity: The filing expects a significant reduction in revenue from expiries in 2026 through 2030, with the pace expected to accelerate. The 2026 impact is expected to be $1.5 billion.
- U.S. pricing policy: Eliquis's government-set Medicare price took effect January 1, 2026, and Ibrance, Xtandi and Xeljanz were chosen for later years under the Inflation Reduction Act (IRA). Pfizer also signed a voluntary "most favored nation" agreement to align certain U.S. prices more closely with other developed countries. The final binding terms are still being negotiated, and its three-year tariff grace period depends on further U.S. manufacturing investment.
- COVID and vaccine policy: Comirnaty and Paxlovid demand depends on infection rates and vaccine recommendations. In January 2026, the CDC reduced the number of immunizations routinely recommended for all U.S. children.
- Debt and deal risk: Pfizer borrowed to fund the Seagen and Metsera acquisitions. The filing says that debt can reduce financial flexibility and lead to credit rating pressure. It also flags impairment risk on acquired pipeline assets, which were approximately $21.8 billion.
- Oxbryta: The sickle cell drug was withdrawn globally in September 2024. In October 2025 the European regulator recommended that its authorization stay suspended, and discussions with the FDA are ongoing.
What management is watching
- Its 2026 priorities are maximizing the value of key transactions, delivering on critical R&D milestones, investing for growth after 2028, and scaling AI across the business.
- Cost programs are a major lever. The cost realignment program is expected to deliver approximately $5.7 billion in total net savings through 2026, with $600 million of that still to come. The manufacturing program targets approximately $1.5 billion by the end of 2027.
- Synergy targets are approximately $1 billion of annual savings from Seagen and approximately $600 million from Metsera, both by the end of 2026.
- Pfizer expects to spend approximately $2.5 billion on property, plant and equipment in 2026, and a final $2.6 billion tax payment is due April 15, 2026.
- Management points investors to Adjusted income and Adjusted diluted EPS, and says lower COVID demand is already built into its 2026 financial guidance.
What the latest 10-Q says
A plain-English read of Management's Discussion (and any new or changed risk factors) in the 10-Q for the quarter ended September 27, 2026, filed November 3, 2026. Figures are as the filing reports them. Read the filing on SEC.gov
The quarter in brief
Pfizer's third-quarter 2026 total revenues were $16.6 billion, relatively flat against $16.7 billion a year earlier, as falling COVID-19 and Prevnar sales offset growth in Eliquis, Padcev and the Vyndaqel family. Excluding Comirnaty and Paxlovid, total revenues increased 7% operationally (a measure that removes currency effects). The company also announced new cost-savings phases.
How the business did
- Revenue: Total revenues decreased $71 million in the quarter. For the first nine months they rose 2% to $46.1 billion from $45.0 billion. Eliquis reached $2,523 million, up 25% operationally on higher U.S. net price and lower rebates. Padcev reached $720 million, up 55%, and the Vyndaqel family $1,773 million, up 12%.
- Declines: Paxlovid fell to $449 million, down 63%, on lower COVID-19 infections. Comirnaty fell to $808 million, down 29% operationally. The Prevnar family fell to $1,564 million, down 10%, on lower U.S. vaccination rates and adult market share erosion.
- Profit: Pre-tax income from continuing operations was $3.4 billion versus $3.3 billion. For nine months it was $5.9 billion versus $9.2 billion, mainly because of intangible asset impairments, legal charges and higher contingent consideration (payments owed to sellers of acquired businesses), partly offset by a net gain on the sale of the ViiV investment. Diluted EPS was $0.56 versus $0.62 in the quarter. Adjusted diluted EPS, which leaves out items such as intangible amortization and restructuring, was $0.87 in both quarters.
- Spending and cash: Research and development expenses rose 18% to $3,016 million, led by oncology and obesity candidates, and acquired in-process R&D included a $650 million charge for the Innovent agreement. Nine-month operating cash flow was $8,825 million versus $6,356 million. There were no share repurchases in the nine months, and a $0.43 per share dividend was declared in October 2026.
What management is watching
- Cost programs: The company announced $1.0 billion of additional savings under its cost realignment program, to be realized from 2027 through 2029, with one-time costs of approximately $2.0 billion. A new manufacturing phase targets approximately $1.5 billion of savings, with one-time costs of approximately $4.0 billion.
- Patent expiries, pricing and tariffs: Management expects an unfavorable revenue impact of approximately $1.1 billion in 2026 from exclusivity expiries, with the pace expected to accelerate over the next few years. It is tracking Medicare negotiated prices and an HHS 340B pilot program expected to begin in January 2027. Under agreements with the U.S. Government, the Section 232 tariff rate for Pfizer products is zero until January 20, 2029, though the company says there is no assurance trade measures will not change.
- Capital and measures: Management expects leverage to stay around current levels or modestly higher, with buybacks possible only after de-levering. It points investors to Adjusted income and Adjusted diluted EPS.
Follow PFE in Kortex
The Kortex app shows PFE's price, options chain and IV rank, and answers your questions from live market data and SEC filings.
Free to download.
Learn the strategies
More stock briefs
For education only, not financial advice. Options involve risk and are not suitable for every investor.